Eli Lilly’s Mounjaro is reported to have overtaken Merck’s Keytruda as the world’s top-selling drug, based on first-quarter 2026 sales. Business Standard and India Today both cite Mounjaro’s quarterly revenue of $8.7 billion for Lilly. In the same reporting period, Merck’s Keytruda is described as generating $7.9 billion. The comparison indicates that Mounjaro outsells Keytruda by about $0.8 billion in the first quarter of 2026. The outlets frame the update as a shift in the ranking of leading global pharmaceuticals by sales, with Mounjaro moving ahead of the long-standing top spot held by Keytruda. The reports focus on the sales figures themselves and do not provide additional context on drivers such as prescription growth, pricing, or market factors. Both articles present the same core claim: Mounjaro is now the highest-selling drug globally, surpassing Keytruda in the cited quarter.